

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Martin EIGENTHALER *et al.*) Group Art Unit: Unassigned
)
Application No.: Unassigned (Divisional of) Examiner: Unassigned
Application No. 09/530,864))
)
Filed: Herewith)
)
For: ANTIBODIES AGAINST)
PHOSPHORYLATED VASP)
(VASODILATOR-STIMULATED)
PHOSPHOPROTEIN),)
HYBRIDOMA CELLS FOR THEIR)
PREPARATION, AND THEIR USE)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), applicant brings to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed within three months of the filing date of the above-referenced application.

Copies of the listed documents were previously submitted in a prior application, application no. 09/530,864, filing date May 5, 2000, upon which applicant relies for the benefits provided in 35 U.S.C. § 120. Applicant respectfully requests that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicant determines that the cited documents do not constitute "prior art" under United States law, applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.


If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: September 19, 2003

By:


Anthony J. Tridico
Reg. No. 45,958

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	5281.1666-01	Appln. No.	Unassigned (Divisional of Application No. 09/530,864)
Applicant	Martin EIGENTHALER <i>et al.</i>		
Filing Date	Herewith	Group:	Unassigned

U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
	5,599,681	4 Feb. 1997	Epstein et al.			

FOREIGN PATENT DOCUMENTS

Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
WO 93/21230	28 Oct. 1993	WIPO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Abel et al. ; "Monoclonal antibodies against the focal adhesion protein VASP revealing epitopes involved in the interaction with two VASP binding proteins and VASP phosphorylation," European Journal of Cell Biology, Vol. 69; No. Suppl. 42, p. 39; 21 st Meeting of the German Society for Cell Biology, Hamburg, Germany, March 24-28 (1996)
	Butt et al. ; "cAMP- and cGMP-dependent protein kinase phosphorylation sites of the focal adhesion vasodilator-stimulated phosphoprotein (VASP) in vitro and in intact human platelets," J. Biol. Chem., Vol. 269, No. 20, pp. 14509-14517 (1994)
	Eigenthaler et al. , "Concentration and regulation of cyclic nucleotides, cyclic-nucleotide-dependent protein kinases and one of their major substrates in human platelets," Eur. J. Biochem., Vol. 205, pp. 471-481 (1992)
	Haffner et al. , "Molecular cloning, structural analysis and functional expression of the proline-rich focal adhesion and microfilament-associated protein VASP", EMBO J., Vol. 14, No. 1, pp. 19-27 (1995)
	Halbrügge et al. , "Stoichiometric and reversible phosphorylation of a 46-kDa protein in human platelets in response to cGMP- and cAMP-elevating vasodilators", J. Biol. Chem., vol. 265, pp. 3088-3093 (1990)
	Horstrup et al. , "Phosphorylation of focal adhesion vasodilator-stimulated phosphoprotein at Ser157 in intact human platelets correlates with fibrinogen receptor inhibition", Eur. J. Biochem., Vol. 225, pp. 21-27 (1994)
	Jarchau T. et al. , "Purification and assays of vasodilator-stimulate phosphoprotein", Methods in Enzymology, Vol. 298, pp. 103-113 (1998)
	Reinhard M. et al. , "The 46-50 kDa Phosphoprotein VASP purified from human platelets is a novel protein associated with actin filaments and focal contacts ", EMBO Journal, Vol. 11, No. 6, pp. 2063-2070 (1992)
	Smol nski et al. , "Analysis and regulation of vasodilator-stimulated phosphoprotein serine 239 phosphorylation in vitro and in intact cells using a phosphospecific monoclonal antibody", J. Biol. Chem., Vol. 273, No. 32, pp. 20029-20035 (1998)

INFORMATION DISCLOSURE CITATION

Atty. Docket No. 5281.1666-01	Appln. No. Unassigned (Divisional of Application No. 09/530,864)
Applicant Martin EIGENTHALER <i>et al.</i>	
Filing Date Herewith	Group: Unassigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Walter U., "Biochemical parameters of Endothelial Function", Institute for Clinical Biochemistry and Pathobiochemistry, Blick, Würzburg University, pp. 79-81 (1997) (German with English translation)
	Walter U. et al., "Platelet-Vessel wall interactions, focal adhesions, and the mechanism of action of endothelial factors", AAS 45, Mediators in the Cardiovascular System; Regional Ischemia, pp. 255-268 (1995)

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce